These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31839603)

  • 1. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy.
    Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C
    Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis.
    Ren M; Wang C; Sheng D; Shi Y; Jin M; Xu S
    Ann Diagn Pathol; 2017 Apr; 27():57-61. PubMed ID: 28325362
    [No Abstract]   [Full Text] [Related]  

  • 4. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
    Wei H; Fang N; Guo L; Wu Z; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer.
    Zhai X; Li SJ
    Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
    Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation analysis in plasma for early diagnosis in lung adenocarcinoma.
    Jin Y; Lu R; Liu F; Jiang G; Wang R; Zheng M
    Medicine (Baltimore); 2024 Jul; 103(28):e38867. PubMed ID: 38996143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
    Hu H; Zhou Y; Zhang M; Ding R
    Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
    [No Abstract]   [Full Text] [Related]  

  • 11. The Combination of SHOX2 and RASSF1A DNA Methylation Had a Diagnostic Value in Pulmonary Nodules and Early Lung Cancer.
    Xie B; Dong W; He F; Peng F; Zhang H; Wang W
    Oncology; 2024; 102(9):759-774. PubMed ID: 38262380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
    Li N; Zeng Y; Huang J
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1379-1393. PubMed ID: 32266538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
    Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
    Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
    Park S; Kim JY; Lee SH; Suh B; Keam B; Kim TM; Kim DW; Heo DS
    Korean J Intern Med; 2017 May; 32(3):514-522. PubMed ID: 28407465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy.
    Sun X; Yuan W; Hao F; Zhuang W
    Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the SHOX2 and RASSF1A methylation levels with the pathological evolution of early-stage lung adenocarcinoma.
    Zhao J; Lu Y; Ren X; Bian T; Feng J; Sun H; Liu L; She B; Liu Y; Ke H
    BMC Cancer; 2024 Jun; 24(1):687. PubMed ID: 38840077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
    Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Manegold C; Lahm H
    Lung Cancer; 2007 Apr; 56(1):115-23. PubMed ID: 17196704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.